AstronauTx
PrivateLast Round
Series A
Oct 9, 2023
Total Funding Raised
$70.17M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
AstronauTx operates in Healthcare & Life Sciences and is based in London. Its latest recorded funding round was a Series A round in October 2023.
AstronauTx is a biotechnology company that develops small-molecule therapeutics to treat Alzheimer's disease and other neurodegenerative disorders by correcting disrupted brain physiology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AstronauTx Comparables
Compare AstronauTx with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GliaPharm SA | 86% | |
| Muna Therapeutics | 83% | |
| Cellestial Health | 81% |
For institutional investors. Book with your work email.
AstronauTx Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Oct 9, 2023 | ||||
| Grant | Sep 1, 2023 | ||||
| Seed | Mar 24, 2020 | ||||
| Seed | Aug 12, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
AstronauTx Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovate UK | Grant |
| MPM Capital | Series A |
| EQT Life Sciences | Series A |
| UKRI Innovate UK | Grant |
| MPM BioImpact | Series A |
| Albion Capital | Seed |
| Brandon Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 16, 2026
Grew 18% QoQ, from 22 to 26 employees.
- Jan 7, 2026
Adam Rosenberg appointed as Chair of the Board of Directors.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingAug 10, 2026
AstronauTx Ltd. secures exclusive worldwide rights to develop, manufacture and commercialise ATX0926, which is expected to enter IND-enabling studies shortly, following its collaboration with Saniona.
- is_developingAug 10, 2026
AstronauTx Ltd. is developing ATX0926, a candidate delivered through its 2023 collaboration with Saniona to discover treatments for neurological conditions, and the programme is expected to enter IND-enabling studies shortly.
For institutional investors. Book with your work email.
AstronauTx Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about AstronauTx's valuation, stock price, and market status.
Is AstronauTx a public or private company?
AstronauTx is a private company.
What is the current stock price of AstronauTx?
AstronauTx is a private company, so its shares have no public market price. Caplight tracks AstronauTx's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is AstronauTx worth (valuation)?
Valuation information for AstronauTx is not publicly available.
Can I buy AstronauTx stock?
AstronauTx shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was AstronauTx's last funding round?
AstronauTx's most recent funding round was Series A on October 9, 2023.
Who are the main investors in AstronauTx?
Key investors in AstronauTx include Albion Capital.
Will AstronauTx IPO soon?
No public IPO plans have been announced for AstronauTx.
How can I track AstronauTx secondary market activity?
Caplight tracks bids, offers, and trades in AstronauTx's shares on secondary markets.